Samsung Bioepis Settles Patent Disputes with AbbVie, Clearing the Way for the Commercialization of SB5 (Adalimumab) in All Approved Markets Worldwide
Samsung Bioepis’ IMRALDI® expected to launch in Europe on October 16, 2018 INCHEON, Korea–(BUSINESS WIRE)– Samsung Bioepis Co., Ltd. today announced that it has signed...